SageView Advisory Group LLC Acquires New Position in DexCom, Inc. $DXCM

Key Points

• SageView Advisory Group LLC has acquired a new stake in DexCom, Inc., purchasing 3,542 shares valued at around $242,000 during the first quarter.
• Various hedge funds have increased their holdings in DexCom, with Golden State Wealth Management increasing its stake by 211.2%.
• Analysts have mostly rated DexCom as a Buy or Strong Buy, with a consensus target price of $99.89 following recent evaluations.

SageView Advisory Group LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 3,542 shares of the medical device company's stock, valued at approximately $242,000.

Other hedge funds have also added to or reduced their stakes in the company. Golden State Wealth Management LLC increased its stake in DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after acquiring an additional 264 shares during the last quarter. Zions Bancorporation National Association UT bought a new position in DexCom in the first quarter valued at approximately $27,000. Heck Capital Advisors LLC bought a new position in DexCom in the fourth quarter valued at approximately $38,000. Alpine Bank Wealth Management bought a new position in DexCom in the first quarter valued at approximately $40,000. Finally, Private Trust Co. NA increased its stake in DexCom by 99.4% in the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock valued at $46,000 after acquiring an additional 335 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Wall Street Zen cut shares of DexCom from a "strong-buy" rating to a "buy" rating in a research note on Sunday, August 10th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $106.00 target price on shares of DexCom in a research note on Friday, August 1st. UBS Group boosted their target price on shares of DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. Argus started coverage on shares of DexCom in a research note on Thursday, August 21st. They set a "buy" rating and a $100.00 target price on the stock. Finally, Raymond James Financial boosted their target price on shares of DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $99.89.

DexCom Stock Performance

NASDAQ DXCM opened at $76.22 on Friday. The firm's fifty day moving average price is $80.88 and its two-hundred day moving average price is $78.72. The stock has a market cap of $29.89 billion, a PE ratio of 52.93, a PEG ratio of 1.59 and a beta of 1.48. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom's revenue was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity at DexCom

In other news, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the transaction, the executive vice president owned 94,102 shares in the company, valued at approximately $7,555,449.58. The trade was a 0.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction on Monday, July 28th. The stock was sold at an average price of $88.99, for a total transaction of $130,459.34. Following the transaction, the executive vice president owned 106,689 shares in the company, valued at approximately $9,494,254.11. This trade represents a 1.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 15,237 shares of company stock valued at $1,263,480 in the last quarter. Insiders own 0.32% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.